Leukocyte stem cell therapy - Enlivex Therapeutics

Drug Profile

Leukocyte stem cell therapy - Enlivex Therapeutics

Alternative Names: Allocetra; ApoCell; leucocyte-stem-cell-therapy-Enlivex-Therapeutics

Latest Information Update: 23 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hadassah Medical Organization
  • Developer Enlivex Therapeutics; Hadassah Medical Organization
  • Class Cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No
  • Available For Licensing Yes - Graft-versus-host disease

Highest Development Phases

  • Phase II Inflammation
  • Phase I/II Graft-versus-host disease
  • Preclinical Crohn's disease; Gout; Multiple sclerosis; Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 23 Jan 2016 Preclinical trials in Rheumatoid arthritis, Gout and Multiple sclerosis in Israel (IV) before January 2016 (Enlivex Therapeutics Pipeline, January 2016)
  • 06 Jan 2016 Preclinical development for Crohn's disease and Transplant rejection (solid organ) is ongoing in Israel
  • 06 Jan 2016 Phase-II clinical trials in Inflammation (Prevention) in Israel (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top